A new dose of escitalopram is available

Discover how a single 15 mg escitalopram capsule can help your practice

Introducing the first and only
escitalopram 15 mg dose in a single capsule¹*

NOW THERE’S A SIMPLE WAY

Discover Escitalopram Capsules 15 mg for the treatment of
Major Depressive Disorder (MDD) or Generalized Anxiety
Disorder (GAD)
in appropriate patients¹

Dear {{accFname}} {{acclname}}, {{accCredentials)},

[My name is {{userName}}. I am a representative for Almatica Pharma, and I have some information you may be interested in.]

[My name is {{userName}}, a representative for Almatica Pharma, and I’ll be in your area sometime soon.]

[I hope you are doing well. This is {{userName}}, a representative for Almatica Pharma, and I have some new information you may appreciate.]

I’m pleased to introduce you to the first and only escitalopram 15 mg dose—a new strength in a single capsule.¹

Escitalopram Capsules 15 mg offer a new dosing option to help address your appropriate patients’ needs, all in a once-daily, single capsule.¹

Please contact me at {{user.Phone}} or {{userEmailAddress}} to arrange a time that is convenient for you or to ask any questions. I would be more than happy to meet [in person | by phone or video conference | in person or by phone or video conference] when you have availability.

Escitalopram Capsules are only available in a 15 mg strength. Use another escitalopram product for initial dosage, dosage titration, administration of dosages other than 15 mg once daily, and to taper during discontinuation.¹

Learn more about how Escitalopram
Capsules 15 mg
can help support your
appropriate patients¹

IMPORTANT SAFETY INFORMATION

WARNING:

SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.

INDICATIONS FOR USE

Escitalopram Capsules are indicated:

•	For the treatment major depressive disorder (MDD) in adults younger than 65 years of age and pediatric patients 12 years of age and older.
•	For the treatment of generalized anxiety disorder (GAD) in adults younger than 65 years of age.

CONTRAINDICATIONS

Escitalopram is contraindicated in patients

•	concomitantly using a monoamine oxidase inhibitor (MAOI) or within 14 days of stopping an MAOI,
•	concomitantly using pimozide,
•	with a known hypersensitivity to escitalopram or citalopram or any inactive ingredient in Escitalopram Capsules.

WARNINGS AND PRECAUTIONS

Serotonin Syndrome: Escitalopram can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs. Serotonin syndrome can also occur when these drugs are used alone.

Discontinuation Syndrome: Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include: nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible.

Seizures: In clinical trials of another escitalopram product, cases of convulsion have been reported in association with escitalopram treatment. Like other drugs effective in the treatment of MDD, Escitalopram Capsules should be introduced with care in patients with a history of seizure disorder.

Activation of Mania or Hypomania: In patients with bipolar disorder, treating a depressive episode with Escitalopram Capsules or another antidepressant may precipitate a mixed/manic episode.

Hyponatremia: Hyponatremia may occur as a result of treatment. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and was reversible when escitalopram was discontinued. Cases with serum sodium lower than 110 mmol/L have been reported with another escitalopram product. Geriatric patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs (Escitalopram Capsules are not indicated in geriatric patients). Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. Consider discontinuing Escitalopram Capsules in patients with symptomatic hyponatremia and institute appropriate medical intervention.

Increased Risk of Bleeding: Escitalopram Capsules increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may add to the risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages.

Interference with Cognitive and Motor Performance: Because any psychoactive drug may impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Escitalopram Capsules do not affect their ability to engage in such activities.

Angle Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs, including Escitalopram Capsules, may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Avoid use of antidepressants, including Escitalopram Capsules, in patients with untreated anatomically narrow angles.

Use in Patients with Concomitant Illness: Caution is advisable in using escitalopram in patients with diseases or conditions that produce altered metabolism or hemodynamic responses.

In subjects with hepatic impairment, clearance of racemic citalopram was decreased and plasma concentrations were increased. Escitalopram Capsules are not recommended in patients with hepatic impairment.

Pharmacokinetics of escitalopram in patients with a creatinine clearance less than 20 mL/minute has not been evaluated, however, it should be used with caution in such patients.

Sexual Dysfunction: Use of SSRIs, including Escitalopram Capsules, may cause symptoms of sexual dysfunction. In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgasm.

ADVERSE REACTIONS

The most common adverse reactions in clinical trials included: insomnia, ejaculation disorder (primarily ejaculatory delay), nausea, increased sweating, fatigue and somnolence, decreased libido, and anorgasmia.

SELECT USE IN SPECIFIC POPULATIONS

Pregnancy

Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.

Use of Escitalopram Capsules in the month before delivery may be associated with an increased risk of postpartum hemorrhage.

Neonates exposed to SSRIs or SNRIs, including Escitalopram Capsules, late in third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery.

Lactation

Infants exposed to Escitalopram Capsules should be monitored for excess sedation, restlessness, agitation, poor feeding and poor weight gain.

Pediatric Use

The safety and effectiveness of Escitalopram Capsules for the treatment of MDD have not been established in pediatric patients younger than 12 years of age.

Hepatic Impairment

Escitalopram Capsules are not recommended in patients with hepatic impairment.

For additional safety information about Escitalopram Capsules, please see the Full Prescribing Information including Boxed Warning and Medication Guide.

Reference: 1. Escitalopram Capsules 15 mg Prescribing Information. Almatica Pharma LLC; 2025.

Additionally, if you would like to receive any future updates on
Escitalopram Capsules 15 mg,
you can sign up for email alerts here.

Best regards,

Privacy Policy | Terms of Use | Unsubscribe

This email may be considered an advertising or promotional message and is intended for US audiences only.

Escitalopram and the Escitalopram logo are trademarks of Almatica Pharma LLC.

Almatica and the Almatica logo are trademarks or registered trademarks of Alvogen TM S.a.r.l.

This email was sent by:

Almatica Pharma LLC

44 Whippany Road, Suite 300, Morristown, NJ 07960